This week we look at comments from acting Food and Drug Administration commissioner Janet Woodcock on perceptions that the agency is getting tougher on drug companies during the approval process. We also highlight new uses of CRISPR to control gene expression, venture funds focused on life sciences, newly ... READ MORE >
life sciences
5 things to know in life sciences: Week of April 12
For the past few months, we've shared stories of positive developments in the race for COVID-19 vaccines and vaccinations. This week, we look at the long backstory of the challenges that have haunted the AstraZeneca vaccine efforts and why it is so critical for the world that these issues are resolved. We ... READ MORE >
5 things to know in life sciences: Week of April 5
As the months of 2021 tick by, the percentage of Americans vaccinated is rapidly increasing. This offers the hope of a return to more normal life but also raises new questions, including whether companies can mandate vaccines or how we track the virus. We also look at the lack of diversity on the boards ... READ MORE >
5 things to know in life sciences: Week of March 29
Each week, we highlight five things you need to know about in the life sciences industry. Here’s the latest. 1. FTC challenges biopharma merger as antitrust scrutiny grows Less than two weeks after the Federal Trade Commission announced it would be taking a more stringent look at mergers in the ... READ MORE >
CHART OF THE DAY: FTC challenges biopharma merger as antitrust scrutiny grows
Less than two weeks after the Federal Trade Commission announced it would be taking a more stringent look at mergers in the biopharmaceutical industry, the proposed Illumina and Grail merger became only the second vertical merger in 40 years (2017’s proposed merger between AT&T and Time Warner) to be ... READ MORE >
5 things to know in life sciences: Week of March 15
The Federal Trade Commission’s new acting chair, Rebecca Kelly Slaughter, has initiated a review of the agency's processes for approving pharma mergers. This is expected to result in a tougher road for these mergers, as we explain below. We also look at the top drugs losing their exclusivity this year, ... READ MORE >
An evolution of the economy: Living, and adapting, with COVID-19
Over the past year, leaders around the globe have held their breath as the pandemic unfolded and drastic measures were tested, from safety mitigation and scientific developments to unprecedented fiscal stimulus. And now, as we emerge from the cloud of 2020, it is likely the current pandemic will soon pass ... READ MORE >
Understanding the rapid spread of COVID-19 variants
As of March 12, more than 341 million doses of COVID-19 vaccines have been administered globally at a remarkable pace of 8.5 million doses a day, according to Bloomberg. Nearly a third of those vaccinations have occurred in the United States, where we have already administered more than 101 million doses ... READ MORE >
5 things to know in life sciences: Week of March 8
This week we look to make sense of COVID-19 variants. We also examine what appears to be heightened scrutiny on accelerated approvals for some treatments, gaps in the understanding of racial and ethnic representation in vaccine trials, tiny cancer-fighting robots and a new contract development and ... READ MORE >
5 things to know in life sciences: Week of March 1
In this week’s roundup we look at new data coming out of the United Kingdom and Israel on their COVID-19 vaccination programs’ results. The U.K. reported last week promising data on the efficacy of the Pfizer-BioNTech vaccine after just one dose. We also highlight improvements in public perception of the ... READ MORE >